Provided by Tiger Trade Technology Pte. Ltd.

WAVE Life Sciences

3.78
-0.1000-2.58%
Post-market: 3.850.0700+1.85%19:40 EDT
Volume:3.75M
Turnover:14.31M
Market Cap:744.66M
PE:-3.51
High:3.96
Open:3.89
Low:3.77
Close:3.88
52wk High:21.73
52wk Low:3.56
Shares:197.00M
Float Shares:94.77M
Volume Ratio:0.94
T/O Rate:3.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0766
EPS(LYR):-1.2118
ROE:-67.42%
ROA:-33.60%
PB:1.64
PE(LYR):-3.12

Loading ...

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Liquidia Technologies (LQDA) and Abbott Laboratories (ABT)

TIPRANKS
·
Yesterday

Wave Life Sciences Initiated at Buy by Ladenburg Thalmann

Dow Jones
·
Yesterday

Wave Life Sciences Plans Single Two-Year Registrational Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency After FDA Feedback

Reuters
·
Oct 01

Wave Life Sciences - on Track to Share 600 Mg Multidose Cohort Data in Q4 2026

THOMSON REUTERS
·
Oct 01

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for Wve-006 (Rna Editing) in Aatd

THOMSON REUTERS
·
Oct 01

Wave Life Sciences - Plans Two-Year Registration Trial with One-Year Interim Analysis for Accelerated Approval

THOMSON REUTERS
·
Oct 01

Wave Life Sciences - Wve-006 Continues to be Generally Safe and Well Tolerated with no Liver Toxicities

THOMSON REUTERS
·
Oct 01

Ladenburg Thalmann Initiates Wave Life Sciences at Buy With $10 Price Target

MT Newswires Live
·
Oct 01

Wave Life Sciences initiated with a Buy at Ladenburg

TIPRANKS
·
Oct 01

Analysts Offer Insights on Healthcare Companies: Q32 Bio (QTTB) and Wave Life Sciences (WVE)

TIPRANKS
·
Oct 01

Wave Life Sciences Says GSK Selects Hepatology siRNA Candidate Under Collaboration, Triggering $12 Million Milestone Payment

Reuters
·
Sep 30

Wave Life Sciences - to Receive $12 Mln Milestone Payment for Candidate Selection

THOMSON REUTERS
·
Sep 30

Wave Life Sciences Announces GSK’s Selection of Sirna Program to Transition to GSK for Further Development

THOMSON REUTERS
·
Sep 30

Wave Life Sciences - Eligible for up to $375 Mln in Milestones Per Program Plus Tiered Royalties

THOMSON REUTERS
·
Sep 30

Press Release: Wave Life Sciences Announces GSK's Selection of siRNA Program to Transition to GSK for Further Development

Dow Jones
·
Sep 30

Wave Life Sciences initiates Phase 2a combination trial of WVE-007

TIPRANKS
·
Sep 23

Wave Life Sciences Starts Phase 2a Trial of WVE-007 with Tirzepatide for Obesity

Reuters
·
Sep 23

Wave Life Sciences Initiates Phase 2a Combination Trial of Wve-007 (Galnac-Sirna) with Tirzepatide for Obesity

THOMSON REUTERS
·
Sep 23

Wave Life Sciences - Maintenance Trial of Wve-007 to Start in Second Half of 2026

THOMSON REUTERS
·
Sep 23

Wave Life Sciences Announces Appointment of DR. Monika Vnuk as Chief Business Officer

THOMSON REUTERS
·
Sep 22